LiquidBiopsy provides a risk-free, painless method to dynamically sample patients and sequentially measure response to treatment. This automated rare cell enrichment platform is CLIA-validated and serves as a front-end for NGS and PCR expression analysis, as well as for FISH and IHC and enumeration/scanning workflows.
More about LiquidBiopsy >>
Powered by LiquidBiopsy, ClearID provides a minimally-invasive tool to monitor cancer patients, enabling more frequent testing and real-time molecular profiling of tumor DNA. Leveraging patented cell enrichment technology, the test analyzes patients' individual mutations to match them with targeted cancer therapies and clinical trials.
More about ClearID >>
See the LiquidBiopsy platform at:
Keep in Touch